TITLE

Medical genetics

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS55
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Structure of the gene coding for the human cyclin-dependent kinase inhibitor P18 (INK4C),' by Alexandre Blais et al.
ACCESSION #
9708236559

 

Related Articles

  • A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Shim, Jaekyung; Lee, Heejeong // Nature;6/27/1996, Vol. 381 Issue 6585, p804 

    Reports that the protein 21, a deoxyribonucleic acid-damage-inducible cell cycle inhibitor, acts as an inhibitor of stress-activated protein kinases (SAPK). Non-enzymatic inhibition of SAPK; Functions of p21.

  • Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. Nguyen, Carvell; Gangning Liang; Nguyen, TuDung T.; Tsao-Wei, Denice; Groshen, Susan; Lübbert, Michael; Jain-Hua Zhou; Benedict, William F.; Jones, Peter A.; Nguyen, C; Liang, G; Nguyen, T T; Tsao-Wei, D; Groshen, S; Lübbert, M; Zhou, J H; Benedict, W F; Jones, P A // JNCI: Journal of the National Cancer Institute;10/3/2001, Vol. 93 Issue 19, p1465 

    Background: Many cancers display alterations in methylation patterns of CpG islands--stretches of DNA rich in CpG dinucleotides often associated with gene promoters that are involved in initiation of gene transcription. This methylation may perturb expression of genes critical to...

  • P21 inhibits cyclin shock. Pines, Jonathon // Nature;6/16/1994, Vol. 369 Issue 6481, p520 

    Discusses the ability of cyclin-dependent kinase inhibitor p21 to inhibit DNA replication directly. Regulation of the progress through the cell cycle by cyclin-dependent protein kinases (CDK); Isolation of all CDK complexes; Ability of p21 to inhibit cyclin-CDK complexes and proliferating-cell...

  • A computational workflow for the design of irreversible inhibitors of protein kinases. Del Rio, Alberto; Sgobba, Miriam; Daniele Parenti, Marco; Degliesposti, Gianluca; Forestiero, Rosetta; Percivalle, Claudia; Conte, Pier Franco; Freccero, Mauro; Rastelli, Giulio // Journal of Computer-Aided Molecular Design;Mar2010, Vol. 24 Issue 3, p183 

    Design of irreversible inhibitors is an emerging and relatively less explored strategy for the design of protein kinase inhibitors. In this paper, we present a computational workflow that was specifically conceived to assist such design. The workflow takes the form of a multi-step procedure that...

  • A chemical switch for inhibitor-sensitive alleles of any protein kinase. Bishop, Anthony C.; Ubersax, Jeffrey A.; Petsch, Dejah T.; Matheos, Dina P.; Gray, Nathanael S.; Blethrow, Justin; Shimizu, Eiji; Tsien, Joe Z.; Schultz, Peter G.; Rose, Mark D.; Wood, John L.; Morgan, David O.; Shokat, Kevan M. // Nature;9/21/2000, Vol. 407 Issue 6802, p395 

    Describes a chemical genetic strategy for sensitizing protein kinases to cell-permeable molecules that do not inhibit wild-type kinases. Methods, which included the analysis of a budding yeast strain carrying an inhibitor-sensitive form of the cyclin-dependent kinase Cdc28 (CDK1) in place of...

  • FRAT1 peptide decreases Aβ production in swAPP751 cells Li, Baolin; Ryder, John; Su, Yuan; Zhou, Yan; Liu, Feng; Ni, Binhui // FEBS Letters;Oct2003, Vol. 553 Issue 3, p347 

    Recently, LiCl has been shown to inhibit amyloid β peptide secretion in association with diminished glycogen synthase kinase β (GSK3β) activity. However, it remains unclear if direct inhibition of GSK3β activity will result in decreased Aβ production.

  • Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in... Schwartz, Gary K.; Hamitovitz-Friedman, Adriana // JNCI: Journal of the National Cancer Institute;9/20/95, Vol. 87 Issue 18, p1394 

    Investigates the ability of safingol, a protein kinase C (PKC) inhibitor, in promoting apoptosis in gastric cancer cells treated with mitomycin C. Role of PKC in the carcinogenesis, tumor cell metastasis and apoptosis; Effect of safingol in combinations with chemotherapy agents in preventing...

  • Preface. McCort, Gary // Current Medicinal Chemistry;Mar2004, Vol. 11 Issue 6, p1 

    Discusses the development of selective protein kinase inhibitors to treat diseases caused by dysregulation of signaling pathways. Role of protein kinases in multiple signal transduction pathways that regulate cell responses, such as growth, metabolism, membrane transport, and adhesion; Details...

  • Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia. Giles, Francis J.; Cortes, Jorge E.; Kantarjian, Hagop M. // Current Molecular Medicine;Nov2005, Vol. 5 Issue 7, p615 

    Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous leukemia (CML). Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase suppressing the Philadelphia chromosome positive clone in CML. Clinical studies have yielded impressive results...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics